1Plosker G, Figgitt D. Rituximab: A review of its use in non Hodgkin's lymphoma and chronic lymphocytic leukaemia [ J ]. Drugs, 2003,63 (8) :803-843.
2Vose JM, Link BK, Grossbard ML, et al. Phase Ⅱ study of rituximab incombination with chop chemotherapy in patients with p reviously untreated, aggressive non-Hodgkin's lymphomal[J]. Clin Oncol, 2001,15,19 (2) :389-397.
3Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment [J]. Hematol J, 2001,2(6) :378-384.
5Plosker GL,Figgitt DP.Rituximab:a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia[J].Drugs,2003,63(8):803-843.
6Stern M,Herrmann R.Overview of monoclonal antibodies in cancer therapy:present and promise[J].Crit Rev Oncol Hematol,2005,54(1):11-29.
7Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684-3688.
9Vitolo U,Chiappella A,Ferreri A J. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP,CNS prophylaxis,and contralateral testis irradiation:final restults of an international phase Ⅱ trial[J].Journal of Clinical Oncology,2011,(20):2766-2772.
10Hou S,Yang W. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China[J].Saudi Medical Journal,2011,(07):675-678.
